Net Product Sales was Aurinia Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $271.35M of $283.06M (96%).
| Product and Service | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Net Product Sales | $103.47M | $158.53M | $216.19M | $271.35M | |||
| Product Revenue, Net | — | — | — | — | |||
| Contract Revenue | — | — | — | — | |||
| License, Collaboration & Royalty Revenue | $30.56M | $16.98M | $18.95M | $11.71M | |||
| License & Contract Revenue | — | — | — | — | |||
| Licensing Revenue | — | — | — | — | |||
| Total | $134.03M | $175.51M | $235.13M | $283.06M |
Aurinia Pharmaceuticals brought in $283.06M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 20.4% from $235.13M in fiscal 2024. Net Product Sales was the largest at $271.35M (95.9%), ahead of License, Collaboration & Royalty Revenue at $11.71M (4.1%).
Compared with fiscal 2024, Net Product Sales grew 25.5% to $271.35M, while License, Collaboration & Royalty Revenue fell 38.2% to $11.71M. From fiscal 2022 to 2025, combined revenue from these lines grew from $134.03M to $283.06M, a compound annual growth rate of 28.3%. Net Product Sales' share of the total rose from 77.2% to 95.9%.
U.S was Aurinia Pharmaceuticals’s largest region in fiscal 2025, bringing in $263.84M of $283.06M (93%).
| Geography | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| U.S | $102.46M | $157.96M | $210.10M | $263.84M | |||
| United States | — | — | — | — | |||
| Japan | $31.48M | $17.56M | $25.04M | $19.21M | |||
| China | — | — | — | — | |||
| Other | $89.00K | — | — | — | |||
| Total | $134.03M | $175.51M | $235.13M | $283.06M |
Aurinia Pharmaceuticals brought in $283.06M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 20.4% from $235.13M in fiscal 2024. U.S was the largest at $263.84M (93.2%), ahead of Japan at $19.21M (6.8%).
Compared with fiscal 2024, U.S grew 25.6% to $263.84M, while Japan fell 23.3% to $19.21M.
Aurinia Pharmaceuticals stopped reporting Other as a separate region after fiscal 2022, when it brought in $89.00K.
United States was Aurinia Pharmaceuticals’s largest region in fiscal 2019, bringing in $200.00K of $318.00K (63%).
| Geography | FY 2018 | FY 2019 |
|---|---|---|
| United States | $345.00K | $200.00K |
| China | $118.00K | $118.00K |
| Total | $463.00K | $318.00K |
Aurinia Pharmaceuticals brought in $318.00K from its two regions in fiscal 2019, the year ended December 31, 2019. That was down 31.3% from $463.00K in fiscal 2018. United States was the largest at $200.00K (62.9%), ahead of China at $118.00K (37.1%).
Compared with fiscal 2018, China grew 0.0% to $118.00K, while United States fell 42.0% to $200.00K.
Aurinia Pharmaceuticals (AUPH) reports its revenue by product and service and by geography. In fiscal 2025, Net Product Sales was its largest product and service line, bringing in $271.35M (95.9% of the total), followed by License, Collaboration & Royalty Revenue at $11.71M (4.1%).
Net Product Sales was Aurinia Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $271.35M, or 95.9% of the $283.06M total across its two product and service lines.
U.S was Aurinia Pharmaceuticals' largest region in fiscal 2025, bringing in $263.84M, or 93.2% of the $283.06M total across its two regions.
Net Product Sales grew faster than License, Collaboration & Royalty Revenue in fiscal 2025, up 25.5% from $216.19M to $271.35M. License, Collaboration & Royalty Revenue fell 38.2% to $11.71M.
Every figure comes from Aurinia Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Aurinia Pharmaceuticals gives it, and years follow its fiscal calendar.
Aurinia Pharmaceuticals' revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.